sutthirat sutthisumdang Oppenheimer has initiated coverage of Vaxart ( NASDAQ: VXRT ) with an outperform rating, citing the company’s focus on oral vaccines. The investment bank said it's optimistic about Vaxart’s ( VXRT ) differentiated oral vaccine platform, particularly its vaccine candidates for norovirus and COVID-19. It noted that oral vaccines could offer better solutions for infectious diseases like norovirus.
Oppenheimer sees the norovirus market as highly attractive and worth around $5B to $10B. It added that it doesn’t view a recent setback for an intramuscular norovirus vaccine being developed by HilleVax ( HLVX ) as negatively reading across to Vaxart’s ( VXRT ) program. The investment bank set its price target for the stock at $4.
More on Vaxart Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding Vaxart Q2 2024 Earnings Preview Biggest stock movers today: ADBE, MSM, RH, and more Seeking Alpha’s Quant Rating on Vaxart.
